ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: A race for an interferon-free regimen to cure HCV infection

Journal of Hepatology

Volumn 59, Issue 4, 2013, Pages 885-888

  Asselah, Tarik ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Chronic hepatitis C; Direct acting antivirals; NS5A inhibitors; Resistance; Safety; Sustained virological response

Indexed keywords

ABT 333; ABT 450; PEGINTERFERON; RIBAVIRIN; RITONAVIR; VIRUS RNA;

CLINICAL ARTICLE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; FATIGUE; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; IN VITRO STUDY; INNATE IMMUNITY; INSOMNIA; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER FUNCTION TEST; NAUSEA; NOTE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RELAPSE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

CHRONIC HEPATITIS C; DAA; DIRECT-ACTING ANTIVIRALS; ERVR; EXTENDED RAPID VIROLOGICAL RESPONSE; NS5A INHIBITORS; PEGIFN; PEGYLATED INTERFERON; RAPID VIROLOGIC RESPONSE; RESISTANCE; RVR; SAFETY; SUSTAINED VIROLOGICAL RESPONSE; SVR;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; PROTEASE INHIBITORS; RIBAVIRIN;

EID: 84884417223     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.05.020     Document Type: Note

References (9)

1. T. Asselah, and P. Marcellin Interferon-free therapy with direct acting antivirals for HCV Liver Int 33 2013 93 104
2. F. Poordad, E. Lawitz, K.V. Kowdley, D.E. Cohen, T. Podsadecki, and S. Siggelkow Exploratory study of oral combination antiviral therapy for hepatitis C N Engl J Med 368 2013 45 53
3. K.V. Kowdley, E. Lawitz, F. Poordad, D.E. Cohen, D. Nelson, and S. Zeuzem Safety and efficacy of interferon-free regimens of ABT-450/R, ABT-267, ABT-333 ± ribavirin in patients with chronic HCV GT1 infection: results from the aviator study J Hepatol 58 2013 A3
4. M. Martinot-Peignoux, C. Stern, S. Maylin, M.P. Ripault, N. Boyer, and L. Leclere Twelve weeks post-treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin Hepatology 51 2010 1122 1126
5. E. Estrabaud, M. Vidaud, P. Marcellin, and T. Asselah Genomics and HCV infection: progression of fibrosis and treatment response J Hepatol 57 2012 1110 1125
6. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, and R. Ghalib Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
7. S. Zeuzem, T. Asselah, P. Angus, J.P. Zarski, D. Larrey, and B. Mullhaupt Efficacy of the protease inhibitor BI201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection Gastroenterology 141 2011 2047 2055
8. M. Sulkowski, D. Gardiner, E. Lawitz, F. Hinestrosa, D. Nelson, and P. Thuluvath Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/- ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 J Hepatol 56 2012 S560 abstract
9. E.J. Gane, C.A. Stedman, R.H. Hyland, X. Ding, E. Svarovskaia, and W.T. Symonds Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N Engl J Med 368 2013 34 44